false Q2 0001382101 --12-31 Accelerated Filer false P10Y P7Y10M17D P8Y10D P6Y8M26D P2Y10M2D P5Y10D P7Y3D P7Y3D 0.7315 0.7289 0.8396 0.7489 0.0016 0.0185 0.0162 0.0255 P6M P6M 0001382101 2020-01-01 2020-06-30 xbrli:shares 0001382101 2020-07-30 iso4217:USD 0001382101 2020-06-30 0001382101 2019-12-31 iso4217:USD xbrli:shares 0001382101 2020-04-01 2020-06-30 0001382101 2019-04-01 2019-06-30 0001382101 2019-01-01 2019-06-30 0001382101 stro:MerckSharpAndDohmeCorporationMember 2020-04-01 2020-06-30 0001382101 stro:MerckSharpAndDohmeCorporationMember 2020-01-01 2020-06-30 0001382101 stro:VaxcyteIncMember 2020-04-01 2020-06-30 0001382101 stro:VaxcyteIncMember 2020-01-01 2020-06-30 0001382101 us-gaap:CommonStockMember 2019-12-31 0001382101 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001382101 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001382101 us-gaap:RetainedEarningsMember 2019-12-31 0001382101 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001382101 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001382101 2020-01-01 2020-03-31 0001382101 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-03-31 0001382101 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001382101 us-gaap:CommonStockMember 2020-03-31 0001382101 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001382101 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0001382101 us-gaap:RetainedEarningsMember 2020-03-31 0001382101 2020-03-31 0001382101 us-gaap:CommonStockMember 2020-04-01 2020-06-30 0001382101 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-06-30 0001382101 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-04-01 2020-06-30 0001382101 us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0001382101 us-gaap:CommonStockMember 2020-06-30 0001382101 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001382101 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-06-30 0001382101 us-gaap:RetainedEarningsMember 2020-06-30 0001382101 us-gaap:CommonStockMember 2018-12-31 0001382101 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001382101 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001382101 us-gaap:RetainedEarningsMember 2018-12-31 0001382101 2018-12-31 0001382101 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0001382101 2019-01-01 2019-03-31 0001382101 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0001382101 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0001382101 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-03-31 0001382101 us-gaap:CommonStockMember 2019-03-31 0001382101 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0001382101 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-03-31 0001382101 us-gaap:RetainedEarningsMember 2019-03-31 0001382101 2019-03-31 0001382101 us-gaap:CommonStockMember 2019-04-01 2019-06-30 0001382101 us-gaap:AdditionalPaidInCapitalMember 2019-04-01 2019-06-30 0001382101 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-04-01 2019-06-30 0001382101 us-gaap:RetainedEarningsMember 2019-04-01 2019-06-30 0001382101 us-gaap:CommonStockMember 2019-06-30 0001382101 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0001382101 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-06-30 0001382101 us-gaap:RetainedEarningsMember 2019-06-30 0001382101 2019-06-30 stro:Segment 0001382101 stro:PublicOfferingMember us-gaap:CommonStockMember 2020-05-14 2020-05-14 0001382101 stro:PublicOfferingMember us-gaap:CommonStockMember 2020-05-14 0001382101 us-gaap:OverAllotmentOptionMember us-gaap:CommonStockMember 2020-05-14 2020-05-14 0001382101 stro:PublicOfferingMember 2020-05-14 2020-05-14 0001382101 stro:VaxcyteIncMember us-gaap:EquitySecuritiesMember stro:VaxcyteCommonStockMember 2020-06-30 0001382101 stro:VaxcyteIncMember us-gaap:EquitySecuritiesMember stro:VaxcyteCommonStockMember 2020-06-01 2020-06-30 0001382101 stro:VaxcyteIncMember stro:VaxcyteCommonStockMember 2020-06-30 0001382101 stro:VaxcyteIncMember stro:VaxcyteCommonStockMember 2020-04-01 2020-06-30 0001382101 stro:VaxcyteIncMember stro:VaxcyteCommonStockMember 2020-01-01 2020-06-30 0001382101 stro:VaxcyteIncMember stro:VaxcyteCommonStockMember stro:RevaluationOfEstimatedFairValueOfVaxcyteCommonStockMember 2020-04-01 2020-06-30 0001382101 stro:VaxcyteIncMember stro:VaxcyteCommonStockMember stro:RevaluationOfEstimatedFairValueOfVaxcyteCommonStockMember 2020-01-01 2020-06-30 0001382101 stro:VaxcyteIncMember stro:VaxcyteCommonStockMember stro:RevaluationOfPriorPreferredStockWarrantConvertedToCommonStockMember 2020-04-01 2020-06-30 0001382101 stro:VaxcyteIncMember stro:VaxcyteCommonStockMember stro:RevaluationOfPriorPreferredStockWarrantConvertedToCommonStockMember 2020-01-01 2020-06-30 0001382101 srt:MinimumMember 2020-01-01 2020-06-30 0001382101 stro:TwoThousandEighteenMerckAgreementMember 2018-08-01 2018-08-31 stro:Program 0001382101 stro:TwoThousandEighteenMerckAgreementMember 2020-01-01 2020-03-31 0001382101 stro:TwoThousandEighteenMerckAgreementMember 2020-01-01 2020-06-30 xbrli:pure 0001382101 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member us-gaap:MeasurementInputDiscountForLackOfMarketabilityMember 2020-06-16 0001382101 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2020-06-30 0001382101 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember 2020-06-30 0001382101 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2020-06-30 0001382101 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member us-gaap:CommercialPaperMember 2020-06-30 0001382101 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2020-06-30 0001382101 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2020-06-30 0001382101 us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2020-06-30 0001382101 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member us-gaap:EquitySecuritiesMember 2020-06-30 0001382101 us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2020-06-30 0001382101 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member us-gaap:AssetBackedSecuritiesMember 2020-06-30 0001382101 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2020-06-30 0001382101 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2020-06-30 0001382101 us-gaap:FairValueMeasurementsRecurringMember 2020-06-30 0001382101 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2020-06-30 0001382101 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2020-06-30 0001382101 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2019-12-31 0001382101 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember 2019-12-31 0001382101 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2019-12-31 0001382101 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member us-gaap:CommercialPaperMember 2019-12-31 0001382101 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0001382101 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0001382101 us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2019-12-31 0001382101 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member us-gaap:AssetBackedSecuritiesMember 2019-12-31 0001382101 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2019-12-31 0001382101 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2019-12-31 0001382101 us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001382101 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2019-12-31 0001382101 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2019-12-31 0001382101 us-gaap:MoneyMarketFundsMember 2020-06-30 0001382101 us-gaap:CommercialPaperMember 2020-06-30 0001382101 us-gaap:CorporateDebtSecuritiesMember 2020-06-30 0001382101 us-gaap:AssetBackedSecuritiesMember 2020-06-30 0001382101 us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember 2020-06-30 0001382101 us-gaap:CashEquivalentsMember 2020-06-30 0001382101 stro:MarketableSecuritiesMember 2020-06-30 0001382101 us-gaap:MoneyMarketFundsMember 2019-12-31 0001382101 us-gaap:CommercialPaperMember 2019-12-31 0001382101 us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0001382101 us-gaap:AssetBackedSecuritiesMember 2019-12-31 0001382101 us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember 2019-12-31 0001382101 us-gaap:CashEquivalentsMember 2019-12-31 0001382101 stro:MarketableSecuritiesMember 2019-12-31 0001382101 srt:MaximumMember 2020-01-01 2020-06-30 0001382101 srt:MaximumMember 2019-01-01 2019-12-31 0001382101 stro:BristolMyersSquibbCompanyBMSMember stro:CollaborationAndLicenseAgreementsAndSupplyAgreementsMember 2020-04-01 2020-06-30 0001382101 stro:BristolMyersSquibbCompanyBMSMember stro:CollaborationAndLicenseAgreementsAndSupplyAgreementsMember 2019-04-01 2019-06-30 0001382101 stro:BristolMyersSquibbCompanyBMSMember stro:CollaborationAndLicenseAgreementsAndSupplyAgreementsMember 2020-01-01 2020-06-30 0001382101 stro:BristolMyersSquibbCompanyBMSMember stro:CollaborationAndLicenseAgreementsAndSupplyAgreementsMember 2019-01-01 2019-06-30 0001382101 stro:MerckSharpAndDohmeCorporationMember stro:CollaborationAndLicenseAgreementsAndSupplyAgreementsMember 2020-04-01 2020-06-30 0001382101 stro:MerckSharpAndDohmeCorporationMember stro:CollaborationAndLicenseAgreementsAndSupplyAgreementsMember 2019-04-01 2019-06-30 0001382101 stro:MerckSharpAndDohmeCorporationMember stro:CollaborationAndLicenseAgreementsAndSupplyAgreementsMember 2020-01-01 2020-06-30 0001382101 stro:MerckSharpAndDohmeCorporationMember stro:CollaborationAndLicenseAgreementsAndSupplyAgreementsMember 2019-01-01 2019-06-30 0001382101 stro:MerckKGaADarmstadtGermanyMember stro:CollaborationAndLicenseAgreementsAndSupplyAgreementsMember 2020-04-01 2020-06-30 0001382101 stro:MerckKGaADarmstadtGermanyMember stro:CollaborationAndLicenseAgreementsAndSupplyAgreementsMember 2019-04-01 2019-06-30 0001382101 stro:MerckKGaADarmstadtGermanyMember stro:CollaborationAndLicenseAgreementsAndSupplyAgreementsMember 2020-01-01 2020-06-30 0001382101 stro:MerckKGaADarmstadtGermanyMember stro:CollaborationAndLicenseAgreementsAndSupplyAgreementsMember 2019-01-01 2019-06-30 0001382101 stro:VaxcyteIncMember stro:CollaborationAndLicenseAgreementsAndSupplyAgreementsMember 2020-04-01 2020-06-30 0001382101 stro:VaxcyteIncMember stro:CollaborationAndLicenseAgreementsAndSupplyAgreementsMember 2019-04-01 2019-06-30 0001382101 stro:VaxcyteIncMember stro:CollaborationAndLicenseAgreementsAndSupplyAgreementsMember 2020-01-01 2020-06-30 0001382101 stro:VaxcyteIncMember stro:CollaborationAndLicenseAgreementsAndSupplyAgreementsMember 2019-01-01 2019-06-30 0001382101 stro:CollaborationAndLicenseAgreementsAndSupplyAgreementsMember 2020-04-01 2020-06-30 0001382101 stro:CollaborationAndLicenseAgreementsAndSupplyAgreementsMember 2019-04-01 2019-06-30 0001382101 stro:CollaborationAndLicenseAgreementsAndSupplyAgreementsMember 2020-01-01 2020-06-30 0001382101 stro:CollaborationAndLicenseAgreementsAndSupplyAgreementsMember 2019-01-01 2019-06-30 0001382101 stro:CollaborationAndLicenseAgreementsAndSupplyAgreementsMember 2019-12-31 0001382101 stro:CollaborationAndLicenseAgreementsAndSupplyAgreementsMember 2020-06-30 0001382101 2020-07-01 2020-06-30 0001382101 stro:FirstCytokineDerivativeProgramMember stro:MerckSharpAndDohmeCorporationMember 2020-03-01 2020-03-31 0001382101 stro:DevelopmentAndManufacturingServicesMember stro:BristolMyersSquibbCompanyBMSMember 2020-04-01 2020-04-30 0001382101 stro:CelgeneAgreementMember 2014-09-01 2014-09-30 0001382101 stro:CelgeneAgreementMember 2015-03-01 2015-03-31 0001382101 stro:CelgeneAgreementMember 2016-06-01 2016-06-30 0001382101 stro:CelgeneAgreementMember 2017-08-01 2017-08-31 0001382101 stro:CelgeneAgreementMember 2017-09-01 2017-09-30 0001382101 stro:CelgeneAgreementMember 2018-12-01 2018-12-31 0001382101 stro:CelgeneAgreementMember 2019-05-01 2019-05-31 0001382101 stro:CelgeneAgreementMember 2017-08-31 0001382101 stro:CelgeneAgreementMember stro:FirstPerformanceObligationMember 2017-08-31 0001382101 stro:CelgeneAgreementMember stro:FutureServicesOnCollaborationJointSteeringCommitteeMember 2017-08-31 0001382101 stro:CelgeneAgreementMember stro:ThirdPerformanceObligationMember 2017-08-31 0001382101 stro:CelgeneAgreementMember us-gaap:AccountingStandardsUpdate201409Member us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member 2019-01-01 0001382101 stro:PartiallyUnsatisfiedPerformanceObligationsMember 2020-04-01 2020-06-30 0001382101 stro:PartiallyUnsatisfiedPerformanceObligationsMember 2020-01-01 2020-06-30 0001382101 stro:PartiallyUnsatisfiedPerformanceObligationsMember 2019-04-01 2019-06-30 0001382101 stro:PartiallyUnsatisfiedPerformanceObligationsMember 2019-01-01 2019-06-30 0001382101 stro:ResearchAndDevelopmentServicesMember 2020-04-01 2020-06-30 0001382101 stro:ResearchAndDevelopmentServicesMember 2020-01-01 2020-06-30 0001382101 stro:ResearchAndDevelopmentServicesMember 2019-04-01 2019-06-30 0001382101 stro:ResearchAndDevelopmentServicesMember 2019-01-01 2019-06-30 0001382101 stro:CelgeneAgreementMember 2020-06-30 0001382101 stro:CelgeneAgreementMember 2019-12-31 0001382101 stro:TwoThousandEighteenCelgeneMasterServicesAgreementMember 2020-04-01 2020-06-30 0001382101 stro:TwoThousandEighteenCelgeneMasterServicesAgreementMember 2020-01-01 2020-06-30 0001382101 stro:TwoThousandEighteenCelgeneMasterServicesAgreementMember 2019-04-01 2019-06-30 0001382101 stro:TwoThousandEighteenCelgeneMasterServicesAgreementMember 2019-01-01 2019-06-30 0001382101 stro:TwoThousandEighteenMerckAgreementMember stro:MerckSharpAndDohmeCorporationMember 2018-07-01 2018-07-31 0001382101 stro:TwoThousandEighteenMerckAgreementMember stro:MerckSharpAndDohmeCorporationMember 2018-08-01 2018-08-31 0001382101 stro:TwoThousandEighteenMerckAgreementMember stro:MerckSharpAndDohmeCorporationMember 2018-08-31 0001382101 stro:TwoThousandEighteenMerckAgreementMember stro:MerckSharpAndDohmeCorporationMember us-gaap:AccountingStandardsUpdate201409Member 2020-06-30 0001382101 stro:TwoThousandEighteenMerckAgreementMember stro:MerckSharpAndDohmeCorporationMember 2020-01-01 2020-06-30 0001382101 us-gaap:AccountingStandardsUpdate201409Member stro:TwoThousandEighteenMerckAgreementMember stro:CelgeneCorporationMember 2019-01-01 0001382101 stro:TwoThousandEighteenMerckAgreementMember stro:MerckSharpAndDohmeCorporationMember stro:FirstTargetProgramMember 2020-03-01 2020-03-31 0001382101 stro:TwoThousandEighteenMerckAgreementMember stro:MerckSharpAndDohmeCorporationMember stro:SecondTargetProgramMember 2020-03-01 2020-03-31 0001382101 stro:TwoThousandEighteenMerckAgreementMember stro:MerckSharpAndDohmeCorporationMember 2020-03-01 2020-03-31 0001382101 stro:FirstCytokineDerivativeProgramMember stro:MerckSharpAndDohmeCorporationMember 2020-02-01 2020-02-29 0001382101 stro:FirstCytokineDerivativeProgramMember stro:MerckSharpAndDohmeCorporationMember 2020-03-31 0001382101 stro:FirstCytokineDerivativeProgramMember stro:MerckSharpAndDohmeCorporationMember 2020-01-01 2020-03-31 0001382101 stro:TwoThousandEighteenMerckAgreementMember stro:MerckSharpAndDohmeCorporationMember stro:PartiallyUnsatisfiedPerformanceObligationsMember 2020-04-01 2020-06-30 0001382101 stro:TwoThousandEighteenMerckAgreementMember stro:MerckSharpAndDohmeCorporationMember stro:PartiallyUnsatisfiedPerformanceObligationsMember 2020-01-01 2020-06-30 0001382101 stro:TwoThousandEighteenMerckAgreementMember stro:MerckSharpAndDohmeCorporationMember stro:PartiallyUnsatisfiedPerformanceObligationsMember 2019-04-01 2019-06-30 0001382101 stro:TwoThousandEighteenMerckAgreementMember stro:MerckSharpAndDohmeCorporationMember stro:PartiallyUnsatisfiedPerformanceObligationsMember 2019-01-01 2019-06-30 0001382101 stro:TwoThousandEighteenMerckAgreementMember stro:MerckSharpAndDohmeCorporationMember 2020-04-01 2020-06-30 0001382101 stro:TwoThousandEighteenMerckAgreementMember stro:MerckSharpAndDohmeCorporationMember 2019-04-01 2019-06-30 0001382101 stro:TwoThousandEighteenMerckAgreementMember stro:MerckSharpAndDohmeCorporationMember 2019-01-01 2019-06-30 0001382101 stro:TwoThousandEighteenMerckAgreementMember 2020-06-30 0001382101 stro:TwoThousandEighteenMerckAgreementMember 2019-12-31 0001382101 us-gaap:CollaborativeArrangementMember stro:EMDSeronoMember 2014-05-01 2014-05-31 0001382101 stro:MDAAgreementMember stro:EMDSeronoMember 2014-09-01 2014-09-30 0001382101 stro:MDAAgreementMember stro:EMDSeronoMember 2020-01-01 2020-06-30 0001382101 stro:EMDSeronoMember 2020-06-30 0001382101 stro:EMDSeronoMember 2020-01-01 2020-06-30 0001382101 stro:MilestonePaymentAndSupplyAgreementMember stro:EMDSeronoMember 2020-04-01 2020-06-30 0001382101 stro:MilestonePaymentAndSupplyAgreementMember stro:EMDSeronoMember 2020-01-01 2020-06-30 0001382101 stro:MilestonePaymentAndSupplyAgreementMember stro:EMDSeronoMember 2019-04-01 2019-06-30 0001382101 stro:MilestonePaymentAndSupplyAgreementMember stro:EMDSeronoMember 2019-01-01 2019-06-30 0001382101 stro:ResearchAndDevelopmentServicesMember stro:EMDSeronoMember 2020-04-01 2020-06-30 0001382101 stro:ResearchAndDevelopmentServicesMember stro:EMDSeronoMember 2020-01-01 2020-06-30 0001382101 stro:ResearchAndDevelopmentServicesMember stro:EMDSeronoMember 2019-04-01 2019-06-30 0001382101 stro:ResearchAndDevelopmentServicesMember stro:EMDSeronoMember 2019-01-01 2019-06-30 0001382101 stro:PartiallyUnsatisfiedPerformanceObligationsMember stro:EMDSeronoMember 2019-04-01 2019-06-30 0001382101 stro:PartiallyUnsatisfiedPerformanceObligationsMember stro:EMDSeronoMember 2019-01-01 2019-06-30 0001382101 stro:MDAAgreementMember stro:EMDSeronoMember 2020-06-30 0001382101 stro:MDAAgreementMember stro:EMDSeronoMember 2019-12-31 0001382101 stro:SupplyAgreementMember stro:VaxcyteIncMember 2020-04-01 2020-06-30 0001382101 stro:SupplyAgreementMember stro:VaxcyteIncMember 2020-01-01 2020-06-30 0001382101 stro:SupplyAgreementMember stro:VaxcyteIncMember 2019-04-01 2019-06-30 0001382101 stro:SupplyAgreementMember stro:VaxcyteIncMember 2019-01-01 2019-06-30 0001382101 stro:ResearchDevelopmentAndCommercializationAgreementMember stro:TheLeukemiaLymphomaSocietyIncMember 2018-08-01 2018-08-31 0001382101 stro:TheLeukemiaLymphomaSocietyIncMember 2020-01-01 2020-06-30 0001382101 stro:LoanAndSecurityAgreementMember stro:OxfordFinanceLimitedLiabilityCompanyAndSiliconValleyBankMember stro:AugustTwoThousandSeventeenLoanMember 2017-08-31 stro:Installment 0001382101 stro:LoanAndSecurityAgreementMember stro:OxfordFinanceLimitedLiabilityCompanyAndSiliconValleyBankMember stro:AugustTwoThousandSeventeenLoanMember stro:MarchTwoThousandNineteenMember 2017-08-01 2017-08-31 0001382101 stro:LoanAndSecurityAgreementMember stro:OxfordFinanceLimitedLiabilityCompanyAndSiliconValleyBankMember stro:AugustTwoThousandSeventeenLoanMember stro:MarchTwoThousandNineteenMember 2020-01-01 2020-06-30 0001382101 stro:AugustTwoThousandSeventeenLoanMember stro:FloatingRateMember 2017-08-01 2017-08-31 0001382101 stro:AugustTwoThousandSeventeenLoanMember us-gaap:LondonInterbankOfferedRateLIBORMember 2017-08-01 2017-08-31 0001382101 stro:AugustTwoThousandSeventeenLoanMember us-gaap:LondonInterbankOfferedRateLIBORMember 2020-01-01 2020-06-30 0001382101 stro:SeriesERedeemableConvertiblePreferredStockMember 2018-10-01 0001382101 stro:TwoThousandSeventeenWarrantsMember 2018-07-31 0001382101 stro:LoanAndSecurityAgreementMember stro:OxfordFinanceLimitedLiabilityCompanyAndSiliconValleyBankMember stro:AugustTwoThousandSeventeenLoanMember 2019-12-31 0001382101 stro:LoanAndSecurityAgreementMember stro:OxfordFinanceLimitedLiabilityCompanyAndSiliconValleyBankMember stro:TermALoanMember 2020-02-29 0001382101 stro:LoanAndSecurityAgreementMember stro:OxfordFinanceLimitedLiabilityCompanyAndSiliconValleyBankMember stro:TermALoanMember 2020-02-01 2020-02-29 0001382101 srt:MaximumMember stro:LoanAndSecurityAgreementMember stro:OxfordFinanceLimitedLiabilityCompanyAndSiliconValleyBankMember stro:TermLoansMember 2020-02-29 0001382101 srt:MinimumMember stro:LoanAndSecurityAgreementMember stro:OxfordFinanceLimitedLiabilityCompanyAndSiliconValleyBankMember stro:TermBLoanMember 2020-02-01 2020-02-29 0001382101 stro:LoanAndSecurityAgreementMember stro:OxfordFinanceLimitedLiabilityCompanyAndSiliconValleyBankMember stro:TermLoansMember 2020-02-01 2020-02-29 0001382101 stro:LoanAndSecurityAgreementMember stro:OxfordFinanceLimitedLiabilityCompanyAndSiliconValleyBankMember stro:TermLoansMember 2020-01-01 2020-06-30 0001382101 us-gaap:LondonInterbankOfferedRateLIBORMember stro:LoanAndSecurityAgreementMember stro:OxfordFinanceLimitedLiabilityCompanyAndSiliconValleyBankMember stro:TermLoansMember 2020-02-01 2020-02-29 0001382101 stro:LoanAndSecurityAgreementMember stro:OxfordFinanceLimitedLiabilityCompanyAndSiliconValleyBankMember stro:TermLoansMember 2020-02-29 0001382101 stro:LoanAndSecurityAgreementMember stro:OxfordFinanceLimitedLiabilityCompanyAndSiliconValleyBankMember 2020-02-29 0001382101 stro:LoanAndSecurityAgreementMember stro:OxfordFinanceLimitedLiabilityCompanyAndSiliconValleyBankMember 2020-02-01 2020-02-29 0001382101 stro:LoanAndSecurityAgreementMember stro:OxfordFinanceLimitedLiabilityCompanyAndSiliconValleyBankMember 2020-06-30 0001382101 stro:MerckSharpAndDohmeCorporationMember stro:SutroBiopharmaINCMember srt:MaximumMember 2020-05-14 0001382101 stro:VaxcyteIncMember srt:MaximumMember 2020-06-16 0001382101 stro:RestrictedCommonStockUnitsIssuedAndOutstandingMember 2020-06-30 0001382101 stro:RestrictedCommonStockUnitsIssuedAndOutstandingMember 2019-12-31 0001382101 stro:TwoThousandFourAndTwoThousandEighteenEquityIncentivePlanMember 2020-06-30 0001382101 stro:TwoThousandFourAndTwoThousandEighteenEquityIncentivePlanMember 2019-12-31 0001382101 stro:TwoThousandEighteenEmployeeStockPurchasePlanMember 2020-06-30 0001382101 stro:TwoThousandEighteenEmployeeStockPurchasePlanMember 2019-12-31 0001382101 us-gaap:WarrantMember 2020-06-30 0001382101 us-gaap:WarrantMember 2019-12-31 0001382101 2018-10-30 0001382101 stro:OxfordFinanceLimitedLiabilityCompanyAndSiliconValleyBankMember stro:SeriesDTwoRedeemableConvertiblePreferredStockMember stro:LoanAndSecurityAgreementMember 2017-08-31 0001382101 stro:OxfordFinanceLimitedLiabilityCompanyAndSiliconValleyBankMember stro:SeriesERedeemableConvertiblePreferredStockMember stro:LoanAndSecurityAgreementMember 2017-08-31 0001382101 stro:OxfordFinanceLimitedLiabilityCompanyAndSiliconValleyBankMember stro:SeriesERedeemableConvertiblePreferredStockMember stro:LoanAndSecurityAgreementMember 2017-08-01 2017-08-31 0001382101 us-gaap:SeriesCPreferredStockMember 2018-09-29 2018-10-01 0001382101 stro:SeriesERedeemableConvertiblePreferredStockMember 2018-09-29 2018-10-01 0001382101 us-gaap:SeriesCPreferredStockMember 2018-10-01 0001382101 stro:OxfordFinanceLimitedLiabilityCompanyMember stro:LoanAndSecurityAgreementMember 2020-02-29 0001382101 stro:SiliconValleyBankMember stro:LoanAndSecurityAgreementMember 2020-02-29 0001382101 stro:TwoThousandEighteenEquityIncentivePlanMember 2018-09-25 0001382101 stro:TwoThousandEighteenEquityIncentivePlanMember 2018-09-24 2018-09-25 0001382101 stro:TwoThousandEighteenEquityIncentivePlanMember srt:MaximumMember 2018-09-24 2018-09-25 0001382101 stro:TwoThousandEighteenEquityIncentivePlanMember 2020-01-01 0001382101 stro:TwoThousandEighteenEquityIncentivePlanMember 2020-06-30 0001382101 stro:TwoThousandFourPlanAndTwoThousandEighteenEquityIncentivePlanMember 2019-12-31 0001382101 stro:TwoThousandFourPlanAndTwoThousandEighteenEquityIncentivePlanMember 2020-01-01 2020-06-30 0001382101 stro:TwoThousandFourPlanAndTwoThousandEighteenEquityIncentivePlanMember 2020-06-30 0001382101 stro:TwoThousandFourPlanAndTwoThousandEighteenEquityIncentivePlanMember 2019-01-01 2019-12-31 0001382101 srt:MinimumMember 2019-01-01 2019-06-30 0001382101 srt:MaximumMember 2019-01-01 2019-06-30 0001382101 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-06-30 0001382101 us-gaap:RestrictedStockUnitsRSUMember 2019-12-31 0001382101 us-gaap:RestrictedStockUnitsRSUMember 2020-06-30 0001382101 stro:TwoThousandEighteenEmployeeStockPurchasePlanMember 2018-09-26 0001382101 stro:TwoThousandEighteenEmployeeStockPurchasePlanMember 2018-09-24 2018-09-26 0001382101 stro:TwoThousandEighteenEmployeeStockPurchasePlanMember srt:MaximumMember 2018-09-24 2018-09-26 0001382101 stro:TwoThousandEighteenEmployeeStockPurchasePlanMember 2020-01-01 0001382101 stro:TwoThousandEighteenEmployeeStockPurchasePlanMember 2020-01-01 2020-06-30 0001382101 stro:TwoThousandEighteenEmployeeStockPurchasePlanMember 2019-01-01 2019-06-30 0001382101 stro:TwoThousandEighteenEmployeeStockPurchasePlanMember 2020-06-30 0001382101 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:EmployeeStockOptionMember 2020-04-01 2020-06-30 0001382101 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:EmployeeStockOptionMember 2019-04-01 2019-06-30 0001382101 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:EmployeeStockOptionMember 2020-01-01 2020-06-30 0001382101 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:EmployeeStockOptionMember 2019-01-01 2019-06-30 0001382101 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:RestrictedStockUnitsRSUMember 2020-04-01 2020-06-30 0001382101 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:RestrictedStockUnitsRSUMember 2019-04-01 2019-06-30 0001382101 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-06-30 0001382101 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-06-30 0001382101 us-gaap:ResearchAndDevelopmentExpenseMember stro:EmployeeStockPurchasePlanMember 2020-04-01 2020-06-30 0001382101 us-gaap:ResearchAndDevelopmentExpenseMember stro:EmployeeStockPurchasePlanMember 2020-01-01 2020-06-30 0001382101 us-gaap:ResearchAndDevelopmentExpenseMember stro:EmployeeStockPurchasePlanMember 2019-01-01 2019-06-30 0001382101 us-gaap:ResearchAndDevelopmentExpenseMember 2020-04-01 2020-06-30 0001382101 us-gaap:ResearchAndDevelopmentExpenseMember 2019-04-01 2019-06-30 0001382101 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-06-30 0001382101 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-06-30 0001382101 us-gaap:GeneralAndAdministrativeExpenseMember us-gaap:EmployeeStockOptionMember 2020-04-01 2020-06-30 0001382101 us-gaap:GeneralAndAdministrativeExpenseMember us-gaap:EmployeeStockOptionMember 2019-04-01 2019-06-30 0001382101 us-gaap:GeneralAndAdministrativeExpenseMember us-gaap:EmployeeStockOptionMember 2020-01-01 2020-06-30 0001382101 us-gaap:GeneralAndAdministrativeExpenseMember us-gaap:EmployeeStockOptionMember 2019-01-01 2019-06-30 0001382101 us-gaap:GeneralAndAdministrativeExpenseMember us-gaap:RestrictedStockUnitsRSUMember 2020-04-01 2020-06-30 0001382101 us-gaap:GeneralAndAdministrativeExpenseMember us-gaap:RestrictedStockUnitsRSUMember 2019-04-01 2019-06-30 0001382101 us-gaap:GeneralAndAdministrativeExpenseMember us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-06-30 0001382101 us-gaap:GeneralAndAdministrativeExpenseMember us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-06-30 0001382101 us-gaap:GeneralAndAdministrativeExpenseMember stro:EmployeeStockPurchasePlanMember 2020-04-01 2020-06-30 0001382101 us-gaap:GeneralAndAdministrativeExpenseMember stro:EmployeeStockPurchasePlanMember 2020-01-01 2020-06-30 0001382101 us-gaap:GeneralAndAdministrativeExpenseMember stro:EmployeeStockPurchasePlanMember 2019-01-01 2019-06-30 0001382101 us-gaap:GeneralAndAdministrativeExpenseMember 2020-04-01 2020-06-30 0001382101 us-gaap:GeneralAndAdministrativeExpenseMember 2019-04-01 2019-06-30 0001382101 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-06-30 0001382101 us-gaap:GeneralAndAdministrativeExpenseMember 2019-01-01 2019-06-30 0001382101 us-gaap:EmployeeStockOptionMember stro:TwoThousandEighteenEquityIncentivePlanMember 2020-06-30 0001382101 us-gaap:EmployeeStockOptionMember stro:TwoThousandEighteenEquityIncentivePlanMember 2019-06-30 0001382101 us-gaap:RestrictedStockUnitsRSUMember stro:TwoThousandEighteenEquityIncentivePlanMember 2020-06-30 0001382101 us-gaap:RestrictedStockUnitsRSUMember stro:TwoThousandEighteenEquityIncentivePlanMember 2019-06-30 0001382101 us-gaap:EmployeeStockOptionMember stro:TwoThousandEighteenEquityIncentivePlanMember 2020-01-01 2020-06-30 0001382101 us-gaap:EmployeeStockOptionMember stro:TwoThousandEighteenEquityIncentivePlanMember 2019-01-01 2019-06-30 0001382101 us-gaap:RestrictedStockUnitsRSUMember stro:TwoThousandEighteenEquityIncentivePlanMember 2020-01-01 2020-06-30 0001382101 us-gaap:RestrictedStockUnitsRSUMember stro:TwoThousandEighteenEquityIncentivePlanMember 2019-01-01 2019-06-30 0001382101 stro:EmployeeStockPurchasePlanMember stro:TwoThousandEighteenEquityIncentivePlanMember 2020-06-30 0001382101 stro:EmployeeStockPurchasePlanMember stro:TwoThousandEighteenEquityIncentivePlanMember 2019-06-30 0001382101 stro:CallOptionPlanMember stro:OptionGrantedInFebruaryTwoThousandAndSeventeenMember 2017-02-01 2017-02-28 0001382101 stro:CallOptionPlanMember stro:OptionGrantedInAugustTwoThousandAndNineteenMember 2019-08-01 2019-08-31 0001382101 stro:CallOptionPlanMember stro:VaxcyteIncMember 2020-06-30 0001382101 stro:CallOptionPlanMember stro:OptionGrantedInFebruaryTwoThousandAndSeventeenMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2017-02-01 2017-02-28 0001382101 stro:CallOptionPlanMember stro:OptionGrantedInFebruaryTwoThousandAndSeventeenMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2017-02-01 2017-02-28 0001382101 stro:CallOptionPlanMember stro:OptionGrantedInFebruaryTwoThousandAndSeventeenMember us-gaap:ShareBasedCompensationAwardTrancheThreeMember 2017-02-01 2017-02-28 0001382101 stro:CallOptionPlanMember stro:OptionGrantedInAugustTwoThousandAndNineteenMember us-gaap:ShareBasedCompensationAwardTrancheThreeMember 2019-08-01 2019-08-31 0001382101 stro:CallOptionPlanMember stro:OptionGrantedInFebruaryTwoThousandAndSeventeenMember stro:ShareBasedCompensationAwardTrancheFourMember 2017-02-01 2017-02-28 0001382101 stro:CallOptionPlanMember stro:OptionGrantedInAugustTwoThousandAndNineteenMember stro:ShareBasedCompensationAwardTrancheFourMember 2019-08-01 2019-08-31 0001382101 stro:CallOptionPlanMember stro:OptionGrantedInAugustTwoThousandAndNineteenMember stro:ShareBasedCompensationAwardTrancheFiveMember 2019-08-01 2019-08-31 0001382101 stro:CallOptionPlanMember stro:OptionGrantedInAugustTwoThousandAndNineteenMember stro:ShareBasedCompensationAwardTrancheSixMember 2019-08-01 2019-08-31 0001382101 stro:CallOptionPlanMember stro:OptionGrantedInFebruaryTwoThousandAndSeventeenMember 2020-01-01 2020-06-30 0001382101 stro:CallOptionPlanMember stro:OptionGrantedInAugustTwoThousandAndNineteenMember 2020-01-01 2020-06-30 0001382101 2019-01-01 2019-12-31 0001382101 stro:CallOptionPlanMember 2020-04-01 2020-06-30 0001382101 stro:CallOptionPlanMember 2020-01-01 2020-06-30 0001382101 stro:CallOptionPlanMember 2019-04-01 2019-06-30 0001382101 stro:CallOptionPlanMember 2019-01-01 2019-06-30 0001382101 us-gaap:EmployeeStockOptionMember 2020-04-01 2020-06-30 0001382101 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-06-30 0001382101 us-gaap:RestrictedStockUnitsRSUMember 2020-04-01 2020-06-30 0001382101 stro:WarrantsToPurchaseCommonStockMember 2020-04-01 2020-06-30 0001382101 stro:WarrantsToPurchaseCommonStockMember 2020-01-01 2020-06-30 0001382101 stro:CommonStockOptionIssuedAndOutstandingMember 2019-01-01 2019-06-30 0001382101 stro:RestrictedStockUnitsIssuedAndOutstandingMember 2019-01-01 2019-06-30 0001382101 stro:WarrantsToPurchaseCommonStockMember 2019-01-01 2019-06-30

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 10-Q

 

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2020

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ________ to ________

Commission File Number: 001-38662

 

SUTRO BIOPHARMA, INC.

(Exact Name of Registrant as Specified in its Charter)

 

 

Delaware

47-0926186

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer

Identification No.)

 

 

310 Utah Avenue, Suite 150

South San Francisco, California

94080

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code: (650) 392-8412

Not Applicable:

(Former name, former address and former fiscal year, if changed since last report)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading Symbol

 

Name of each exchange on which registered

Common stock, $0.001 par value

 

STRO

 

Nasdaq Global Market

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.     Yes      No  

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).     Yes      No  

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

 

  

Accelerated filer

 

Non-accelerated filer

 

  

Smaller reporting company

 

 

 

 

 

Emerging growth company

 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes      No  

As of July 30, 2020, the registrant had 35,879,012 shares of common stock, $0.001 par value per share, outstanding.

 


 

Table of Contents

 

 

 

Page

PART I.

FINANCIAL INFORMATION

 

Item 1.

Financial Statements (Unaudited)

1

 

Condensed Balance Sheets

1

 

Condensed Statements of Operations

2

 

Condensed Statements of Comprehensive Income (Loss)

3

 

Condensed Statements of Stockholders’ (Deficit) Equity

4

 

Condensed Statements of Cash Flows

5

 

Notes to Unaudited Condensed Financial Statements

6

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

26

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

40

Item 4.

Controls and Procedures

40

PART II.

OTHER INFORMATION

 

Item 1.

Legal Proceedings

41

Item 1A.

Risk Factors

41

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

86

Item 3.

Defaults Upon Senior Securities

86

Item 4.

Mine Safety Disclosures

86

Item 5.

Other Information

86

Item 6.

Exhibits

87

Signatures

 

88

 

 

i


 

PART I—FINANCIAL INFORMATION

Item 1. Financial Statements.

Sutro Biopharma, Inc.

Condensed Balance Sheets

(In thousands, except share and per share amounts)

 

 

 

June 30,

 

 

December 31,

 

 

 

2020

 

 

2019

 

 

 

(Unaudited)

 

 

 

 

 

Assets

 

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

65,348

 

 

$

4,960

 

Marketable securities

 

 

136,015

 

 

 

112,904

 

Investment in equity securities

 

 

49,094

 

 

 

 

Accounts receivable (including amounts from related parties of $0 and

   $1,050 as of June 30, 2020 and December 31, 2019, respectively) (1)

 

 

5,102

 

 

 

6,298

 

Prepaid expenses and other current assets

 

 

2,931

 

 

 

4,406

 

Total current assets

 

 

258,490

 

 

 

128,568

 

Property and equipment, net

 

 

11,265

 

 

 

9,633

 

Marketable securities, non-current

 

 

5,647

 

 

 

15,609

 

Other non-current assets

 

 

2,121

 

 

 

2,545

 

Restricted cash

 

 

15

 

 

 

15

 

Total assets

 

$

277,538

 

 

$

156,370

 

Liabilities and Stockholders’ Equity

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

Accounts payable

 

$

4,901

 

 

$

5,584

 

Accrued compensation

 

 

4,520

 

 

 

6,017

 

Deferred revenue—current

 

 

23,503

 

 

 

19,465

 

Debt—current

 

 

 

 

 

1,000

 

Other current liabilities

 

 

2,536

 

 

 

901

 

Total current liabilities

 

 

35,460

 

 

 

32,967

 

Deferred revenue, non-current

 

 

10,562

 

 

 

16,195

 

Deferred rent

 

 

330

 

 

 

409

 

Debt—non-current

 

 

24,281

 

 

 

8,876

 

Other noncurrent liabilities

 

 

148

 

 

 

134

 

Total liabilities

 

 

70,781

 

 

 

58,581

 

Stockholders’ equity:

 

 

 

 

 

 

 

 

Preferred stock, $0.001 par value — 10,000,000 shares authorized

   as of June 30, 2020 and December 31, 2019; 0 shares issued and

   outstanding as of June 30, 2020 and December 31, 2019

 

 

 

 

 

 

Common stock, $0.001 par value — 300,000,000 shares authorized

   as of June 30, 2020 and December 31, 2019; 35,878,928 and

  23,098,969 shares issued and outstanding as of

  June 30, 2020 and December 31, 2019, respectively

 

 

36

 

 

 

23

 

Additional paid-in-capital

 

 

391,791

 

 

 

293,346

 

Accumulated other comprehensive income

 

 

398

 

 

 

165

 

Accumulated deficit

 

 

(185,468

)

 

 

(195,745

)

Total stockholders’ equity

 

 

206,757

 

 

 

97,789

 

Total Liabilities and Stockholders’ Equity

 

$

277,538

 

 

$

156,370

 

 

 

(1)

Merck was a related party until the closing of the Company’s public offering on May 14, 2020.
Vaxcyte (formerly SutroVax) was a related party until the closing of its initial public offering on June 16, 2020.

 

See accompanying notes to unaudited interim condensed financial statements.

1


 

Sutro Biopharma, Inc.

Condensed Statements of Operations

(Unaudited)

(In thousands, except share and per share amounts)

 

 

 

Three Months Ended

 

 

Six Months Ended

 

 

 

June 30,

 

 

June 30,

 

 

 

2020

 

 

2019

 

 

2020

 

 

2019

 

Revenues (including amounts from related

   parties of $0 and $2,813 during the three and six

   months ended June 30, 2020, respectively, and $5,497

   and $10,413 during the three and six months ended

   June 30, 2019, respectively) (1) (2)

 

$

9,469

 

 

$

10,525

 

 

$

16,621

 

 

$

19,154

 

Operating expenses

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

 

17,243

 

 

 

16,143

 

 

 

34,862

 

 

 

31,323

 

General and administrative

 

 

8,643

 

 

 

8,067

 

 

 

17,356

 

 

 

15,782

 

Total operating expenses

 

 

25,886

 

 

 

24,210

 

 

 

52,218

 

 

 

47,105

 

Loss from operations

 

 

(16,417

)

 

 

(13,685

)

 

 

(35,597

)

 

 

(27,951

)

Interest income

 

 

384

 

 

 

1,124

 

 

 

1,025

 

 

 

2,300

 

Unrealized gain on equity securities

 

 

48,860

 

 

 

 

 

 

48,860

 

 

 

 

Interest and other expense, net

 

 

(2,955

)

 

 

(1,232

)

 

 

(4,011

)

 

 

(2,392

)

Net income (loss)

 

$

29,872

 

 

$

(13,793

)

 

$

10,277

 

 

$

(28,043

)

Net income (loss) per share, basic (3)

 

$

1.00

 

 

$

(0.60

)

 

$

0.39

 

 

$

(1.22

)

Net income (loss) per share, diluted (3)

 

$

0.94

 

 

$

(0.60

)

 

$

0.36

 

 

$

(1.22

)

 

 

 

(1)

Includes $0 and $2.8 million, respectively, for the three months and six months ended June 30, 2020 of related party revenue from Merck. Merck was a related party until the closing of the Company’s public offering on May 14, 2020.

 

(2)

Includes $0 and $36,000, respectively, for the three months and six months ended June 30, 2020 of related party revenue from Vaxcyte (formerly SutroVax). Vaxcyte was a related party until the closing of its initial public offering on June 16, 2020.

 

(3)

See Notes 2 and 10 for an explanation of the calculations of our basic and diluted net income (loss) per share, basic and diluted and the weighted-average number of shares used in the computation of the per share amounts.

 

See accompanying notes to unaudited interim condensed financial statements.

2


 

Sutro Biopharma, Inc.

Condensed Statements of Comprehensive Income (Loss)

(Unaudited)

(In thousands)

 

 

 

Three Months Ended

 

 

Six Months Ended

 

 

 

 

June 30,

 

 

June 30,

 

 

 

 

2020

 

 

2019

 

 

2020

 

 

2019

 

 

Net income (loss)

 

$

29,872

 

 

$

(13,793

)

 

$

10,277

 

 

$

(28,043

)

 

Other comprehensive income:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Unrealized gain on available-for-sale securities

 

 

370

 

 

 

157

 

 

 

233

 

 

 

260

 

 

Comprehensive income (loss)

 

$

30,242

 

 

$

(13,636

)

 

$

10,510

 

 

$

(27,783

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

See accompanying notes to unaudited interim condensed financial statements.

3


 

Sutro Biopharma, Inc.

Condensed Statements of Stockholders’ Equity

(Unaudited)

(In thousands, except share amounts)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Accumulated

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Additional

 

 

Other

 

 

 

 

 

 

Total

 

 

 

Preferred Stock

 

 

Common Stock

 

 

Paid-In-

 

 

Comprehensive

 

 

Accumulated

 

 

Stockholders’

 

 

 

Shares

 

 

Amount

 

 

Shares

 

 

Amount

 

 

Capital

 

 

Income (Loss)

 

 

Deficit

 

 

Equity

 

Balances at December 31, 2019

 

 

 

 

$

 

 

 

23,098,969

 

 

$

23

 

 

$

293,346

 

 

$

165

 

 

$

(195,745

)

 

$

97,789

 

Exercise of common stock options

 

 

 

 

 

 

 

 

12,937

 

 

 

 

 

 

56

 

 

 

 

 

 

 

 

 

56

 

Issuance of common stock under Employee Stock

   Purchase Plan

 

 

 

 

 

 

 

 

74,465

 

 

 

 

 

 

646

 

 

 

 

 

 

 

 

 

646

 

Vesting of restricted stock units

 

 

 

 

 

 

 

 

41,050

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Stock-based compensation expense

 

 

 

 

 

 

 

 

 

 

 

 

 

 

2,707

 

 

 

 

 

 

 

 

 

2,707

 

Issuance of common stock warrants in connection

   with debt refinancing

 

 

 

 

 

 

 

 

 

 

 

 

 

 

619

 

 

 

 

 

 

 

 

 

619

 

Net unrealized loss on available-for- sale securities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(137

)

 

 

 

 

 

(137

)

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(19,595

)

 

 

(19,595

)

Balances at March 31, 2020

 

 

 

 

 

 

 

 

23,227,421

 

 

 

23

 

 

 

297,374

 

 

 

28

 

 

 

(215,340

)

 

 

82,085

 

Exercise of common stock options

 

 

 

 

 

 

 

 

1,257

 

 

 

 

 

 

8

 

 

 

 

 

 

 

 

 

8

 

Vesting of restricted stock units

 

 

 

 

 

 

 

 

250

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Stock-based compensation expense

 

 

 

 

 

 

 

 

 

 

 

 

 

 

3,011

 

 

 

 

 

 

 

 

 

3,011

 

Issuance of common stock in connection with

   public offering, net of issuance costs of $6,626

 

 

 

 

 

 

 

 

12,650,000

 

 

 

13

 

 

 

91,398

 

 

 

 

 

 

 

 

 

91,411

 

Net unrealized gain on available-for- sale securities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

370

 

 

 

 

 

 

370

 

Net income

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

29,872

 

 

 

29,872

 

Balances at June 30, 2020

 

 

 

 

$

 

 

 

35,878,928

 

 

$

36

 

 

$

391,791

 

 

$

398

 

 

$

(185,468

)

 

$

206,757

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Accumulated

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Additional

 

 

Other

 

 

 

 

 

 

Total

 

 

 

Preferred Stock

 

 

Common Stock

 

 

Paid-In-

 

 

Comprehensive

 

 

Accumulated

 

 

Stockholders’

 

 

 

Shares

 

 

Amount

 

 

Shares

 

 

Amount

 

 

Capital

 

 

Loss

 

 

Deficit

 

 

Equity

 

Balances at December 31, 2018

 

 

 

 

$

 

 

 

22,848,184

 

 

$

23

 

 

$

281,891

 

 

$

(47

)

 

$

(150,328

)

 

$

131,539

 

Adoption of Accounting Standards Update (ASU)

   No. 2014-09, Revenue from Contracts with

   Customers (Topic 606)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

10,327

 

 

 

10,327

 

Exercise of common stock options

 

 

 

 

 

 

 

 

8,347

 

 

 

 

 

 

42

 

 

 

 

 

 

 

 

 

42

 

Issuance of common stock under Employee Stock

   Purchase Plan

 

 

 

 

 

 

 

 

68,910

 

 

 

 

 

 

671

 

 

 

 

 

 

 

 

 

671

 

Stock-based compensation expense

 

 

 

 

 

 

 

 

 

 

 

 

 

 

2,286

 

 

 

 

 

 

 

 

 

2,286

 

Net unrealized gain on available-for- sale securities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

103

 

 

 

 

 

 

103

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

-

 

 

 

(14,250

)

 

 

(14,250

)

Balances at March 31, 2019

 

 

 

 

 

 

 

 

22,925,441

 

 

$

23

 

 

$

284,890

 

 

$

56

 

 

$

(154,251

)

 

$

130,718

 

Exercise of common stock options

 

 

 

 

 

 

 

 

1,762

 

 

 

 

 

 

10

 

 

 

 

 

 

 

 

 

10

 

Stock-based compensation expense

 

 

 

 

 

 

 

 

 

 

&#